Online citations, reference lists, and bibliographies.
← Back to Search

Dissection Of Signaling Pathways In Fourteen Breast Cancer Cell Lines Using Reverse-Phase Protein Lysate Microarray

M. Akkiprik, Daniel Nicorici, D. Cogdell, Yu Jack Jia, A. Hategan, I. Tabus, O. Yli-Harja, Dihua Yu, A. Sahin, Wei Zhang
Published 2006 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Signal transduction pathways play a crucial role in breast cancer development, progression, and response to different therapies. A major problem in breast cancer therapy is the heterogeneity among different tumor types and cell lines commonly used in preclinical studies. To characterize the signaling pathways of some of the commonly used breast cancer cell lines and dissect the relationship among a number of pathways and some key genetic and molecular events in breast cancer development, such as p53 mutation, ErbB2 expression, and estrogen receptor (ER)/progesterone receptor (PR) status, we performed pathway profiling of 14 breast cancer cell lines by measuring the expression and phosphorylation status of 40 different cell signaling proteins with 53 specific antibodies using a protein lysate array. Cluster analysis of the expression data showed that there was close clustering of phosphatidylinositol 3-kinase, Akt, mammalian target of rapamycin (mTOR), Src, and platelet-derived growth factor receptor β (PDGFRβ) in all of the cell lines. The most differentially expressed proteins between ER- and PR-positive and ER- and PR-negative breast cells were mTOR, Akt (pThr308), PDGFRβ, PDGFRβ (pTyr751), panSrc, Akt (pSer473), insulin-like growth factor-binding protein 5 (IGFBP5), Src (pTyr418), mTOR (pSer2448), and IGFBP2. Many apoptotic proteins, such as apoptosis-inducing factor, IGFBP3, bad, bax, and cleaved caspase 9, were overexpressed in mutant p53-carrying breast cancer cells. Hexokinase isoenzyme 1, ND2, and c-kit were the most differentially expressed proteins in high and low ErbB2-expressing breast cancer cells. This study demonstrated that ER/PR status, ErbB2 expression, and p53 status are major molecules that impact downstream signaling pathways.
This paper references
10.1016/J.EJCA.2005.11.025
The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
E. Tokunaga (2006)
10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N
c‐Src PROTEIN EXPRESSION IS INCREASED IN HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS
B. Verbeek (1996)
10.1002/path.1958
Array‐based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer
C. Gulmann (2006)
10.1007/s00280-005-0108-2
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
R. Schiff (2005)
tor Binding Proteins 5 and 6 ( IGFBP - 5 and 6 ) in Human Breast Cancer Cells
S. V. Allander (1992)
10.1002/(SICI)1097-4644(19991215)75:4<652::AID-JCB11>3.0.CO;2-0
Differential IGF‐independent effects of insulin‐like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells
C. Perks (1999)
10.1073/pnas.2331323100
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays
S. Nishizuka (2003)
10.1002/PMIC.200300600
Protein microarrays: Promising tools for proteomic research
M. Templin (2003)
10.1210/EN.2005-0467
Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion.
V. Russo (2005)
10.1016/0022-4731(87)91183-6
Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue.
A. Hennipman (1989)
10.1038/sj.onc.1204265
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front
C. Paweletz (2001)
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
C. Osborne (2005)
10.1093/JNCI/86.23.1785
Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer.
D. Yee (1994)
10.1093/bioinformatics/19.2.185
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
B. Bolstad (2003)
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.
A. Myoui (2003)
10.1210/ME.2002-0318
Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
X. Cui (2003)
10.1200/JCO.2003.09.099
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
V. Bardou (2003)
10.1158/1078-0432.CCR-05-0637
Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma
C. Gulmann (2005)
10.1124/jpet.106.102004
Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy
N. Rucci (2006)
10.1056/nejm199811263392207
Tamoxifen in the treatment of breast cancer.
C. Osborne (1998)
10.1186/1476-4598-4-7
Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion
E. Lee (2004)
10.1016/S0006-291X(05)80290-6
Identification of the insulin-like growth factor binding proteins 5 and 6 (IGFBP-5 and 6) in human breast cancer cells.
M. Sheikh (1992)
10.1073/pnas.1530509100
Statistical significance for genomewide studies
J. Storey (2003)
10.1200/JCO.2005.02.509
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.
E. Petricoin (2005)
Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes.
H. Wang (2003)
10.1210/ENDO-127-6-2679
Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status.
D. Clemmons (1990)
10.1038/415530a
Gene expression profiling predicts clinical outcome of breast cancer
L. J. Veer (2002)
10.1198/016214502753479248
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
S. Dudoit (2002)
10.1038/sj.bjc.6602862
Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer
H-J Lin (2005)
10.1074/JBC.M301965200
Insulin-like Growth Factor-binding Protein-5 Inhibits the Growth of Human Breast Cancer Cells in Vitro and in Vivo*
A. Butt (2003)
10.1002/cncr.20095
Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis
X. Hao (2004)
Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5.
S. Allander (1994)
10.1128/MCB.23.6.1994-2008.2003
Two Domains of the Progesterone Receptor Interact with the Estrogen Receptor and Are Required for Progesterone Activation of the c-Src/Erk Pathway in Mammalian Cells
C. Ballaré (2003)
10.1109/TSP.2006.873719
Nonlinear modeling of protein expressions in protein arrays
I. Tabus (2006)
10.1056/NEJM199811263392207
Tamoxifen in the Treatment of Breast Cancer
O. Ck (1998)
10.1038/ncponc0485
Technology Insight: pharmacoproteomics for cancer—promises of patient-tailored medicine using protein microarrays
J. Wulfkuhle (2006)
10.1016/S0016-5085(08)80193-X
AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells.
S. Tanno (2001)
10.1016/S1097-2765(01)00304-5
Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases.
V. Boonyaratanakornkit (2001)
10.1111/J.2517-6161.1995.TB02031.X
Controlling the false discovery rate: a practical and powerful approach to multiple testing
Y. Benjamini (1995)
10.1002/PMIC.200500555
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays
R. Jiang (2006)
AKT Activation Upregulates Insulin - like Growth Factor I Receptor Expression and Promotes Invasiveness of Human Pancreatic Cancer Cells
C. Ballare (2001)
10.1002/ijc.21358
Akt is frequently activated in HER2/neu‐positive breast cancers and associated with poor prognosis among hormone‐treated patients
E. Tokunaga (2006)
10.1016/S0166-4328(01)00297-2
Controlling the false discovery rate in behavior genetics research
Y. Benjamini (2001)



This paper is referenced by
10.1158/0008-5472.CAN-09-3108
Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer.
B. Ahn (2010)
10.1007/s11523-007-0054-5
The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts
D. Behrens (2007)
10.1002/prca.200800032
Applications of protein microarrays for biomarker discovery
Niroshan Ramachandran (2008)
10.1586/epr.10.99
Protein microarrays and novel detection platforms
Harini Chandra (2011)
10.1002/prca.200780035
Reverse‐phase protein arrays for application‐orientated cancer research
U. Korf (2009)
10.4137/CIN.S9055
Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots
E. Neeley (2012)
10.1093/bioinformatics/btp174
Variable slope normalization of reverse phase protein arrays
E. Neeley (2009)
Molecular cloning and functional studies of tenascin-C isoforms containing the fibronectin-type III repeat additional domain 1 (AD1)
D. Guttery (2009)
Pharmacologie moléculaire du sunitinib et du vandetanib, deux inhibiteurs d’activité kinase, dans le cancer médullaire de la thyroïde
S. Broutin (2011)
10.1002/prca.200780011
Phosphoproteomics: A possible route to novel biomarkers of breast cancer
M. Metodiev (2008)
10.1007/978-1-60327-375-6_29
Protein Microarray Technology
C. H. Clarke (2008)
10.1002/ijc.25116
Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid
R. Chu (2010)
Statistical modeling of protein lysate array data
Ji Yeon Yang (2010)
The role of Y-box binding protein 1 in prostate cancer
Morgan R. Pokorny (2013)
Lack of Protein Kinase C alpha is associated with poor prognosis in pediatric T-ALL: a phosphoproteomic discovery
Gloria Milani (2012)
NPTEL WEB COURSE – ADVANCED CLINICAL PROTEOMICS
S. Srivastava (2013)
10.1016/j.cellsig.2014.01.017
Stratification and delineation of gastric cancer signaling by in vitro transcription factor activity profiling and integrative genomics.
Jayaprakash Periasamy (2014)
10.1007/s12032-014-0427-4
Human mammary microenvironment better regulates the biology of human breast cancer in humanized mouse model
Ming-jie Zheng (2015)
Mitochondrial complex 1 gene analysis in keratoconus
Dhananjay Pathak (2011)
10.1016/J.TIBTECH.2007.08.005
Ecotoxicological risk assessment using DNA chips and cellular reporters.
Johan Robbens (2007)
10.1186/bcr2116
Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer
M. Akkiprik (2008)
10.1021/acs.nanolett.5b01785
Differentiation of Normal and Cancer Cell Adhesion on Custom Designed Protein Nanopatterns.
Utku Horzum (2015)
10.3389/fendo.2015.00025
IGF-Binding Protein 2 – Oncogene or Tumor Suppressor?
Adam Pickard (2015)
10.1586/erm.10.110
Systematic antibody and antigen-based proteomic profiling with microarrays
B. Ayoglu (2011)
10.1038/srep01449
A physical sciences network characterization of non-tumorigenic and metastatic cells
David B. Jenolyn F. Wadih Shashanka Joseph E. Robert H. Agus Alexander Arap Ashili Aslan Austin Backman Be (2013)
Semantic Scholar Logo Some data provided by SemanticScholar